|
Characteristic
|
n
|
(%)
|
|---|
|
Gender
| | |
|
Male
|
54
|
75.0
|
|
Female
|
18
|
25.0
|
|
Age (year)
| | |
|
Median
|
60
| |
|
Range
|
21-80
| |
|
ECOG PS
| | |
|
0
|
23
|
31.9
|
|
1
|
49
|
68.1
|
|
Hepatitis
| | |
|
No
|
2
|
2.8
|
|
Yes
|
70
|
97.2
|
|
HBV
|
52
|
72.2
|
|
HCV
|
6
|
8.3
|
|
Others
|
12
|
16.7
|
|
Liver cirrhosis
| | |
|
No
|
16
|
22.2
|
|
Yes
|
56
|
77.8
|
|
PVTT
| | |
|
No
|
30
|
41.7
|
|
Yes
|
42
|
58.3
|
|
AFP (IU/mL)
| | |
|
<400
|
48
|
66.7
|
|
≥400
|
24
|
33.3
|
|
Child-Pugh class
| | |
|
A
|
54
|
75.0
|
|
B
|
18
|
25.0
|
|
AJCC stage
| | |
|
II
|
12
|
16.7
|
|
III
|
53
|
73.6
|
|
IVA
|
7
|
9.7
|
|
Previous treatment
| | |
|
No
|
7
|
9.7
|
|
Yes
|
65
|
90.3
|
|
TACE
|
63
|
87.5
|
|
RFA
|
7
|
9.7
|
|
PEI
|
7
|
9.7
|
|
Surgery
|
9
|
12.5
|
|
Treatment after RT
| | |
|
No
|
31
|
43.1
|
|
Yes
|
41
|
56.9
|
|
TACE
|
40
|
55.6
|
|
RFA
|
2
|
2.8
|
|
PEI
|
2
|
2.8
|
|
Systemic CTx
|
3
|
4.2
|
|
Radiation dose
| | |
|
40 Gy/10 fxs
|
6
|
8.3
|
|
45 Gy/10 fxs
|
10
|
13.9
|
|
50 Gy/10 fxs
|
56
|
77.8
|
- Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status; HBV hepatitis B virus; HCV hepatitis C virus; PVTT portal vein tumor thrombosis; AFP alpha-fetoprotein; AJCC American Joint Committee on Cancer; TACE transcatheter arterial chemoembolization; RFA radiofrequency ablation; PEI percutaneous ethanol injection; RT radiotherapy; CTx chemotherapy; fxs fractions.
